Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

13  Enrolling
25  Total Trials
Pinned
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With...
Enrolling
Conditions: Type 2 diabetes
Trial Name
TRANSCEND-T2D-2
Drugs: retatrutide, semaglutide
Age
≥18 years
Phase
III
Pinned
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)
Enrolling
Conditions: Obesity, Overweight, Type 2 Diabetes, Sleep Apnea
Trial Name
TRIUMPH-2
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACH...
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-3
Drugs: Orforglipron, Semaglutide
Age
≥18 years
Phase
III
Pinned
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (A...
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-1
Drugs: Orforglipron
Age
≥18 years
Phase
III
Pinned
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Enrolling
Conditions: Diabetic Peripheral Neuropathy
Drugs: LY3556050
Age
≥18 years
Phase
II
Pinned
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight a...
Enrolling
Conditions: Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
Trial Name
ACHIEVE-4
Drugs: Orforglipron (LY3502970), Insulin Glargine
Age
≥18 years
Phase
III
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Enrolling
Conditions: Type 2 Diabetes, Obesity
Drugs: Tirzepatide (LY3298176)
Age
18 - 75 years
Phase
II
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Enrolling
Conditions: Type 2 diabetes, Healthy volunteers
Drugs: LY3938577, insulin degludec
Age
18 - 70 years
Phase
I
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREA...
Enrolling
Conditions: Obesity, Overweight, Chronic Kidney Disease with or without Type 2 Diabetes
Trial Name
TREASURE-CKD
Drugs: Tirzepatide
Age
≥18 years
Phase
II
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Withou...
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-5
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-J
Drugs: Orforglipron
Age
≥18 years
Phase
III
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glyc...
Enrolling
Conditions: Type 2 diabetes
Trial Name
TRANSCEND-T2D-3
Drugs: retatrutide
Age
≥18 years
Phase
III
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control Wit...
Enrolling
Conditions: Type 2 diabetes
Trial Name
ACHIEVE-2
Drugs: dapagliflozin, orforglipron
Age
≥18 years
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
3  Not Yet Enrolling
25  Total Trials
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Not Yet Enrolling
Conditions: Type 2 diabetes
Drugs: LY3209590
Age
10 - 17 years
Phase
I
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise ...
Not Yet Enrolling
Conditions: Type 2 Diabetes
Trial Name
TRANSCEND-T2D-1
Drugs: retatrutide
Age
≥18 years
Phase
III
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Not Yet Enrolling
Conditions: Type 1 diabetes, Healthy volunteers
Drugs: LY3938577, insulin degludec, insulin lispro
Age
18 - 64 years
Phase
I
9 
Completed Enrollment
25  Total Trials
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
Completed Enrollment
Conditions: Obesity, Overweight, Type 2 Diabetes
Trial Name
ATTAIN-2
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin fo...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
QWINT-1
Drugs: LY3209590, Insulin Glargine, Insulin Efsitora Alfa
Age
≥18 years
Phase
III
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First ...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
QWINT-2
Drugs: LY3209590, Insulin Degludec, Insulin Efsitora Alfa
Age
≥18 years
Phase
III
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
SURPASS-CVOT
Drugs: Tirzepatide, Dulaglutide
Age
≥40 years
Phase
III
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal ...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
QWINT-3
Drugs: LY3209590, Insulin Degludec, Insulin Efsitora Alfa
Age
≥18 years
Phase
III
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
SURPASS-SWITCH
Drugs: Dulaglutide, Tirzepatide
Age
≥18 years
Phase
IV
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily I...
Completed Enrollment
Conditions: Type 1 Diabetes
Trial Name
QWINT-5
Drugs: Insulin degludec, Insulin Efsitora Alfa, LY3209590
Age
≥18 years
Phase
III
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
SURPASS-EARLY
Drugs: Antihyperglycemic medication, Tirzepatide
Age
≥18 years
Phase
IV
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled Wit...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
SURPASS-PEDS
Drugs: Tirzepatide
Age
10 - 18 years
Phase
III